DNA vs. HALO, CRSP, IBRX, KRYS, IMVT, SWTX, APGE, ACLX, IOVA, and DNLI
Should you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), ImmunityBio (IBRX), Krystal Biotech (KRYS), Immunovant (IMVT), SpringWorks Therapeutics (SWTX), Apogee Therapeutics (APGE), Arcellx (ACLX), Iovance Biotherapeutics (IOVA), and Denali Therapeutics (DNLI). These companies are all part of the "biological products, except diagnostic" industry.
Ginkgo Bioworks (NYSE:DNA) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, community ranking, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.
Ginkgo Bioworks has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.
Ginkgo Bioworks currently has a consensus price target of $1.90, suggesting a potential upside of 259.51%. Halozyme Therapeutics has a consensus price target of $53.14, suggesting a potential upside of 19.99%. Given Ginkgo Bioworks' higher possible upside, equities analysts clearly believe Ginkgo Bioworks is more favorable than Halozyme Therapeutics.
Halozyme Therapeutics received 480 more outperform votes than Ginkgo Bioworks when rated by MarketBeat users. Likewise, 69.19% of users gave Halozyme Therapeutics an outperform vote while only 47.92% of users gave Ginkgo Bioworks an outperform vote.
78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 15.1% of Ginkgo Bioworks shares are owned by company insiders. Comparatively, 2.4% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Halozyme Therapeutics has higher revenue and earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ginkgo Bioworks had 1 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 8 mentions for Ginkgo Bioworks and 7 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.35 beat Ginkgo Bioworks' score of 0.29 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.
Halozyme Therapeutics has a net margin of 36.94% compared to Ginkgo Bioworks' net margin of -409.11%. Halozyme Therapeutics' return on equity of 225.71% beat Ginkgo Bioworks' return on equity.
Summary
Halozyme Therapeutics beats Ginkgo Bioworks on 14 of the 18 factors compared between the two stocks.
Get Ginkgo Bioworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ginkgo Bioworks Competitors List
Related Companies and Tools
